[go: up one dir, main page]

BE905957A - NEW FACTOR FOR REGULATING CELL GROWTH. - Google Patents

NEW FACTOR FOR REGULATING CELL GROWTH.

Info

Publication number
BE905957A
BE905957A BE0/217546A BE217546A BE905957A BE 905957 A BE905957 A BE 905957A BE 0/217546 A BE0/217546 A BE 0/217546A BE 217546 A BE217546 A BE 217546A BE 905957 A BE905957 A BE 905957A
Authority
BE
Belgium
Prior art keywords
cell growth
human
regulating cell
cultured
new factor
Prior art date
Application number
BE0/217546A
Other languages
French (fr)
Original Assignee
Oncogen Soc En Commandite
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncogen Soc En Commandite filed Critical Oncogen Soc En Commandite
Publication of BE905957A publication Critical patent/BE905957A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Nouvelles compositions pour régulation de la croissance cellulaire, obtenues à partir de leucocytes, p. ex. lymphocytes de sang périphérique humain ou lignées de lymphomes histiocytiques humains cultivés avec un ou des inducteurs. Le peptide apparaissant naturellement est obtenu par purification du milieu conditionné de ces cellules et possède une activité d'inhibition ou de stimulation sélectives pour certaines lignées de cellules. Le polypeptide est isolé à partir de milieux conditionnés de LSP humains cultivés ou de lignées de cellules de lymphomes histiocytiques, est synthétisé ou est préparé par clonage du gène dans un hote approprié.New compositions for regulating cell growth, obtained from leukocytes, p. ex. human peripheral blood lymphocytes or human histiocytic lymphoma lines cultured with one or more inducers. The naturally occurring peptide is obtained by purification of the conditioned medium of these cells and has a selective inhibition or stimulation activity for certain cell lines. The polypeptide is isolated from conditioned media of cultured human LSPs or histiocytic lymphoma cell lines, is synthesized or is prepared by cloning the gene into an appropriate host.

BE0/217546A 1985-12-20 1986-12-17 NEW FACTOR FOR REGULATING CELL GROWTH. BE905957A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81123585A 1985-12-20 1985-12-20
US93528386A 1986-11-26 1986-11-26

Publications (1)

Publication Number Publication Date
BE905957A true BE905957A (en) 1987-06-17

Family

ID=27123452

Family Applications (1)

Application Number Title Priority Date Filing Date
BE0/217546A BE905957A (en) 1985-12-20 1986-12-17 NEW FACTOR FOR REGULATING CELL GROWTH.

Country Status (29)

Country Link
JP (1) JP2559035B2 (en)
KR (1) KR920005920B1 (en)
CN (1) CN1017626B (en)
AT (1) AT400444B (en)
AU (2) AU601168B2 (en)
BE (1) BE905957A (en)
CA (1) CA1340296C (en)
CH (1) CH675727A5 (en)
CY (1) CY1608A (en)
DE (2) DE3643428A1 (en)
DK (1) DK174094B1 (en)
ES (1) ES2003180A6 (en)
FI (1) FI91484C (en)
FR (1) FR2597108B1 (en)
GB (1) GB2185485B (en)
GR (1) GR862936B (en)
HK (1) HK65691A (en)
HU (1) HU210694B (en)
IE (1) IE59415B1 (en)
IL (1) IL81017A (en)
IT (1) IT1213428B (en)
LU (1) LU86718A1 (en)
NL (1) NL8603209A (en)
NO (1) NO174556C (en)
NZ (1) NZ218634A (en)
OA (1) OA08494A (en)
PT (1) PT83986B (en)
SE (1) SE505059C2 (en)
SG (1) SG60891G (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4645828A (en) * 1984-03-23 1987-02-24 Oncogen Platelet related growth regulator
US5681930A (en) * 1985-12-20 1997-10-28 Bristol-Myers Squibb Company Anti-oncostatin M monoclonal antibodies
NZ218634A (en) * 1985-12-20 1991-06-25 Oncogen Peptide identified by its cross reactivity with a cell growth factor, dna, antibodies to peptide and test kits
NZ226799A (en) * 1987-11-06 1991-08-27 Oncogen Breast cancer inhibitory factor and method for inhibiting proliferation of neoplastic cells and compositions therefor
IL97622A (en) * 1990-03-29 1997-06-10 Oncogen Limited Partnership Se Monoclonal antibodies that inhibit growth of kaposi's sarcoma
NO303226B1 (en) * 1990-03-29 1998-06-15 Bristol Myers Squibb Co Monoclonal antibody to Onkostatin M, as well as DNA molecule, cell line and hybridoma
WO1992002556A1 (en) * 1990-08-02 1992-02-20 Michael Valentine Agrez Human colon cancer cell-derived fibroblast elongation factor
IL107040A0 (en) * 1992-09-25 1993-12-28 Lilly Co Eli Modified platelet factor-4

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4132776A (en) * 1978-02-15 1979-01-02 University Patents, Inc. Delivery of immunologically active components of transfer factor
US4645828A (en) * 1984-03-23 1987-02-24 Oncogen Platelet related growth regulator
NZ218634A (en) * 1985-12-20 1991-06-25 Oncogen Peptide identified by its cross reactivity with a cell growth factor, dna, antibodies to peptide and test kits

Also Published As

Publication number Publication date
GB2185485A (en) 1987-07-22
CH675727A5 (en) 1990-10-31
SE8605459D0 (en) 1986-12-18
PT83986B (en) 1989-07-31
AU6660886A (en) 1987-06-25
GB8629997D0 (en) 1987-01-28
CA1340296C (en) 1998-12-29
FR2597108A1 (en) 1987-10-16
NO865178L (en) 1987-06-22
DK174094B1 (en) 2002-06-10
NL8603209A (en) 1987-07-16
NO865178D0 (en) 1986-12-19
DE3643428A1 (en) 1987-09-24
JP2559035B2 (en) 1996-11-27
LU86718A1 (en) 1988-07-14
HU210694B (en) 1995-06-28
AT400444B (en) 1995-12-27
CY1608A (en) 1992-04-03
FR2597108B1 (en) 1991-02-15
IT1213428B (en) 1989-12-20
IL81017A0 (en) 1987-03-31
DE3643428C2 (en) 1990-08-23
IE59415B1 (en) 1994-02-23
HUT43103A (en) 1987-09-28
ES2003180A6 (en) 1988-10-16
JPS62236498A (en) 1987-10-16
NO174556B (en) 1994-02-14
OA08494A (en) 1988-07-29
NZ218634A (en) 1991-06-25
IE863345L (en) 1987-06-20
SE8605459L (en) 1987-06-21
PT83986A (en) 1987-01-01
ATA340686A (en) 1995-05-15
FI91484C (en) 1994-07-11
AU601168B2 (en) 1990-09-06
CN86108955A (en) 1987-12-02
KR920005920B1 (en) 1992-07-24
AU6776590A (en) 1991-03-14
HK65691A (en) 1991-08-23
IT8622787A0 (en) 1986-12-19
FI91484B (en) 1994-03-31
NO174556C (en) 1994-05-25
IL81017A (en) 1993-01-14
DK615386D0 (en) 1986-12-18
SG60891G (en) 1991-08-23
GR862936B (en) 1987-10-28
DE3645095C2 (en) 1993-11-18
DK615386A (en) 1987-06-21
GB2185485B (en) 1990-07-04
KR870005645A (en) 1987-07-06
CN1017626B (en) 1992-07-29
FI865156A (en) 1987-06-21
FI865156A0 (en) 1986-12-17
AU639048B2 (en) 1993-07-15
SE505059C2 (en) 1997-06-16

Similar Documents

Publication Publication Date Title
Chan et al. A novel abl protein expressed in Philadelphia chromosome positive acute lymphoblastic leukaemia positive acute lymphoblastic leukaemia
Bartram et al. Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia
ATE153382T1 (en) RECOMBINANT DNA PROCESS AND HOST CELLS
IL157644A0 (en) Method for the purification of a protein preparation with erythropoietin activity
EP0176588A4 (en) Platelet related growth regulator.
IL76625A0 (en) Substituted propane-phosphonous acid compounds
DE69032406D1 (en) Wound medication containing heparanase
BE905957A (en) NEW FACTOR FOR REGULATING CELL GROWTH.
Hilfiker et al. Biologic properties of chromatographically separated murine thymoma-derived Interleukin 2 and colony-stimulating factor.
BE887529A (en) POLYPEPTIDE PREPARING, MICROBIOLOGICALLY WITH GENETIC INFORMATION SEQUENCE, MICROORGANISMS CONTAINING SUCH GENETIC INFORMATION AND THEIR PREPARATION METHODS
DE69333079D1 (en) EXPRESSION CASSETTE AND PLASMIDE FOR AN EXPRESSION SPECIFIC FOR CLOSURE CELLS AND THEIR USE FOR INTRODUCTION TO TRANSGENIC PLANT CELLS AND PLANTS
DE3660021D1 (en) Plant for the anaerobic purification of waste water
KR890700672A (en) Platelet-related growth regulators
ATE86635T1 (en) PURIFICATION OF RECOMBINANT INTERLEUKIN-1.
Minato et al. Regulation of the growth and functions of cloned murine large granular lymphocyte lines by resident macrophages.
Cohen et al. Linkage between blood coagulation and inflammation: stimulation of neutrophil tissue kallikrein by thrombin
ATE52540T1 (en) USE OF GLUTAMINE IN THE FORM OF ITS DI- AND TRIPEPTIDES IN CELL CULTURE MEDIUM.
Cox et al. Assignment of the gene for beta 2-microglobulin (B2m) to mouse chromosome 2.
ES8800725A1 (en) Monoclonal antibodies to tissue plasminogen activator derived from human normal cells.
SILLETTI et al. Autocrine motility factor-receptor in human bladder-carcinoma-gene-expression, loss of cell-contact regulation and chromosomal mapping
ATE53237T1 (en) ENLARGING VIRAL DNA SEGMENTS.
Perlmutter et al. Expression of complement proteins C2 and factor B in transfected L cells.
MacKintosh et al. Proteins synthesized before and after fertilization in sea urchin eggs
Ikeda et al. RNA Polymerase in Vegetative Cells of Bacillus subtilis II. New Polypeptide Factors, FI and FII, Stimulating In Vitro RNA Synthesis Directed by Phage M2 DNA
Martinez et al. Growth inhibition and morphologic modulation of human fibroblastlike cells by erythromycin

Legal Events

Date Code Title Description
RE20 Patent expired

Owner name: *ONCOGEN SOC.EN COMMANDITE

Effective date: 20061217